Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 May 2019 | Story Lacea Loader | Photo Robin Thuynsma
Mr Nikile Ntsababa
Mr Nikile Ntsababa.

Mr Nikile Ntsababa took up the position of Registrar at the University of the Free State (UFS) on 1 May 2019. His appointment was approved by the UFS Council during its quarterly meeting on 15 March 2019.
 
“Mr Ntsababa is an experienced and knowledgeable university registrar with 10 years of senior management experience in institutional compliance, regulatory compliance, academic administration, and university records management. His history of senior roles in the higher-education sector has the advantage of a very good understanding regarding the dynamics, context, and challenges that the position of registrar brings,” says Prof Francis Petersen, Rector and Vice-Chancellor of the UFS.
 
He holds a Postgraduate Diploma in Records and Archives Management from the University of Fort Hare, a Master of Public Administration from Nelson Mandela University, and a Bachelor of Arts in Communication from the University of Fort Hare. Some of the further certification and short courses he has completed includes a Certificate in International Higher Education Management from Vanderbilt University, Tennessee State in the USA, and a Compliance Management Certificate from the University of Cape Town. He is a Certified Ethics Officer.
 
Mr Ntsababa was Registrar at the Cape Peninsula University of Technology (CPUT) from April 2012 to April 2019; before that he was Deputy Registrar at CPUT from April 2009 to March 2012. He also served as Director of Governance at the University of Fort Hare from September 2007 to March 2009, and as Faculty Manager: Management and Commerce at the University of Fort Hare from January 2004 to August 2007.   
 
“I look forward to working at the UFS and to share my knowledge and experience of higher-education legislation and the associated regulatory processes, requirements, and trends in the higher-education sector,” says Mr Ntsababa.

Released by:

Lacea Loader (Director: Communication and Marketing)

Telephone: +27 51 401 2584 | +27 83 645 2454

Email: news@ufs.ac.za | loaderl@ufs.ac.za

Fax: +27 51 444 6393



News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept